Showing 1031-1040 of 1211 results for "".
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- Johnson & Johnson Vision Showcases 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-30-new-sets-of-scientific-data-on-myopia-refractive-technologies-iols-and-more-at-arvo/2481554/Johnson & Johnson Vision announced that it is presenting 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmolog
- Bausch + Lomb to Present New Data on Products and Pipeline Programs at ARVOhttps://modernod.com/news/bausch-lomb-to-present-new-data-on-products-and-pipeline-programs-at-arvo/2481545/Bausch + Lomb announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023. The presentations include results from the 12-m
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023https://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-at-arvo-2023/2481541/Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-cryst
- Regeneron to Present New Data and Analyses of High-Dose Aflibercept at ARVO 2023https://modernod.com/news/regeneron-to-present-new-data-and-analyses-of-high-dose-aflibercept-at-arvo-2023/2481537/Regeneron Pharmaceuticals and its collaborator Bayer announced that aflibercept 8 mg and Eylea (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27. Among the presentations wi
- Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of Gene Therapy OCU400, for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-12-trial-of-gene-therapy-ocu400-for-the-treatment-of-rp-and-lca/2481534/Ocugen announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) wit
- Ocumension Therapeutics Submits a New Drug Application for Zerviate in Chinahttps://modernod.com/news/ocumension-therapeutics-submits-a-new-drug-application-for-zerviate-in-china/2481533/Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) for approval to commercialize Zerviate (cetirizine ophthalmic solution), 0.24%, in China, for ocular itching associated with allergic conjunctivitis. The approval p
- Atsena Therapeutics Announces 6-Month Data from Phase 1/2 Clinical Trial of ATSN-101 to be Presented at ARVOhttps://modernod.com/news/atsena-therapeutics-announces-6-month-data-from-phase-12-clinical-trial-of-atsn-101-to-be-presented-at-arvo/2481523/Atsena Therapeutics announced that 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmol
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.